Search Results
Communicating Queer Chinese Identities: A Qualitative Investigation of the Visibility and Intelligibility of Transnational Queer Women in the United States
In today’s climate of anti-Asian hate, we believe that it is important to uncover different aspects of what “being Chinese” could look like. To this end, we are looking for individuals who self-identify as ethnically Chinese, woman, and a member of the LGBTQIA+ community to participate in a one-time 90-minute online interview to learn about what they do in their regular, everyday life to try to show or tell others about who they are. As part of the study, we will ask interviewees to share some visual images (e.g., photos, drawings, etc.) that they own as a way of elaborating on the ways that they communicate their self-identity in everyday life.
Chinese ethnicity
Woman
Non-woman
Not Chinese ethnicity
Translational Study on Temperature and Solvent Effects on Electronic Cigarette-Derived Oxidants
Determine if free radicals produced by electronic cigarettes or conventional cigarettes impact inflammation and oxidative stress responses in users.
Subjects will come to the Clinical Research Center at Hershey and if they are a nicotine user they will bring their product/device (cigarette or e-cigarette) with them. Healthy volunteers will answer the same questionnaires and provide the same samples but will not use any nicotine during their visit. They will provide blood, urine, buccal cell, saliva, exhaled breath and exhaled breath condensate samples. They will be videotaped using their own devices and they will answer questionnaires. This is a one-time visit that will last around 2 hours.
100
For cigarette or e-cigarette users: No plan on quitting in the next 3 months
For e-cigarette users: E-cigarette use for more than 6 months
For cigarette users: Cigarette use for more than 6 months
For
Uncontrolled substance abuse
Pregnant or nursing
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo- Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention- Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to learn more about the use of an investigational drug for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in preschool-aged (4-5 years old) children.
If after Visit 1 (Screening) your child is found to be eligible to take the study drug, he/she will need to come to the study center for 7 additional visits (Visits# 2-8; 6 weeks) and you will receive a follow-up phone call one week after your child’s last study visit (or after your child takes the last capsule of study drug). Most visits will be scheduled 1 week apart. Every participant will take 1 capsule each day for 6 weeks. Your child will either take one SPN-812 capsule every day for 6 weeks or a Placebo capsule every day for 6 weeks.
$650
Subject’s parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent, including a signed Informed Consent Form
Has a primary diagnosis of ADHD
Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school or child care program)
Is not currently receiving a behavioral intervention for ADHD at the time of screening nor plans to receiving a behavioral intervention for ADHD throughout their study
Has a current diagnosis of a major neurological disorder.
History of Bipolar Disorder diagnosed in a first degree relative.
Has global development delay or intellectual disability by medical history.
Has body mass index > 95th percentile for the subject’s age and gender.
The role of ocular and limb motor inhibition for dexterous motor control
In this project, participants will perform experiments where they will be asked to look at salient virtual targets and make reaching movements to those targets, while ignoring other visual stimuli presented to them.
During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Penn State University, on a single day.We will ask you to perform an eye-hand coordination task using a robot. You will sit in a modified chair and grasp a handle that permits you to move your hand leftward, rightward, towards and away from your body. A display system will project visual targets into the same plane as your hands, which will allow you to interact virtually with the visual targets. These targets will be either bright or dark and you will be instructed to look at some of these targets (while ignoring others) and make reaching movements to some of these targets.
20
Male and female participants who volunteer for the study and provide informed consent.
Participants will be right-hand dominant individuals.
They will have normal or corrected-to-normal vision.
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest.
Any history of musculoskeletal disorders
Eye or vision problem
Cognitive impairment such that informed consent cannot be obtained, or that participant would not be safe with the protocol.
Medication that could make the participant drowsy or tired during the experiment
The Biomechanics of Golf Performance
The purpose of this study is to determine what golf equipment and swing characteristics best predict playing ability in a population of golfers. Golfers will hit shots with various clubs while the movement of their body, the club, and the ball are tracked.
Participants will come to the Penn State Golf Teaching and Research Center or the Penn State Golf Courses and hit golf shots using their driver, 7 iron, and putter. A golf monitor will be used to track the ball trajectory. The movements of participant's body, club, and ball will be measured in three-dimensions as they swing. Participants will receive brief feedback from a Class-A PGA Professional upon completion.
Participants will receive brief feedback from a Class-A PGA Professional upon completion.
Between ages of 18-75
Physically able to play a full round of golf (i.e., 18 holes)
Not between ages of 18-75
Not physically able to play a full round of golf (i.e., 18 holes)
The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program.
The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program. The aims of the PRIDE Program are to: 1. Create a centralized Biorepository using extra blood obtained from a clinically-ordered, or another IRB approved research protocol initiated blood draw, leftover biospecimens that are removed during medically indicated procedures or a saliva sample from consented participants that do not have clinically ordered blood draws or a medical procedure. 2. Construct a dynamic database of health and related data (via both manual and electronic abstraction) from consented participants. 3. Establish a mechanism for approving use of the banked biospecimens for future research.
The participant will meet with PRIDE Program team member in person to join the study. The participant with supply a saliva sample for the program. There is no compensation for joining the PRIDE Program.
Ability of patient, child and/or parent to understand or complete the consent process
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
Radiation treatment and hormonal therapy vs. Radiation treatment, hormonal therapy plus Enzalutamide in post-prostatectomy cancer recurrences.
Radiation treatment and hormonal therapy vs. Radiation treatment, hormonal therapy plus Enzalutamide in post-prostatectomy cancer recurrences
PSA level (≥0.2 ng/mL) within 90 days prior to registration.
Hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration.
At least 1 of the following features: • Gleason score of 8-10 • Seminal vesicle invasion • Locoregional node involvement at radical prostatectomy • Persistently elevated PSA post-RP nadir
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
A082002 Randomized Phase II/III of immunotherapy with or without SBRT PD-L1 negative NSCLC (22-026)
To assess if SBRT improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage NSCLC patients with PD-L1 TPS <1% who receive immunotherapy with or without chemotherapy
We are asking you to take part in a research study. This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.
No prior systemic chemotherapy or immunotherapy for advanced NSCLC
Not pregnant and not nursing
No known history of Hepatitis B or Hepatitis C
Platelet Count ≥ 100,000/mm3
Current pneumonitis or history of non-infectious pneumonitis that required steroids
Prior allogeneic tissue/solid organ transplant.
Age < 18 years
ECOG Performance Status over 3
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) (PSCI# 21-207) (NRG-HN009)
The purpose of this study is to compare two usual treatment approaches to your head and neck cancer: high-dose cisplatin given every 3 weeks with radiation to low-dose cisplatin given weekly with radiation. The first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks. The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach. There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.
he first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks. The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach. There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.
Age ≥ 18
Zubrod (ECOG) performance status of 0-1 within 14 days prior to registration
Adequate hematologic function within 30 days prior to registration
Adequate renal function within 30 days prior to registration defined as calculated creatinine clearance (CrCl) ≥ 50 mL/min by the Cockcroft-Gault formula
Definitive clinical or radiologic evidence of distant metastatic disease
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Pregnancy and individuals unwilling to discontinue nursing
Future of Construction Workplace Health Monitoring
This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for construction workplace health monitoring.
There will be one in person visit, you will be asked to sit still for 3 minutes and then move your skin for another 3 minutes.
be over 18 years old.
must understand English.
from Penn State, University Park
cannot understand English
under 18 years old
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
This is a drug study that will examine if inhaled treprostinil is save and effective in people diagnosed with Progressive Pulmonary Fibrosis.
You will be required to attend 8 in-person visits at the Hershey Medical Center over the span of approximately one year. During the study you will have physical examinations, complete questionnaires, review your medical history and current medications, have vital signs and ECGs taken, have blood tests performed, complete pulmonary function testing, and potentially have a high resolution CT scan done. You will take the inhaled treprostinil or placebo daily at home throughout the study.
600
Evidence of progression of pulmonary fibrosis in the last 24 months
Evidence of obstructive pulmonary disease
Concomitant use of both nintedanib and pirfenidone is not permitted
Received any PAH-approved therapy in last 60 days
Receiving >10 L/min of oxygen supplementation
BCC018: A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
This study is being done to learn if it is safe to add naxitamab to standard therapy during the Induction phase of care for patients with newly diagnosed high-risk neuroblastoma. Naxitmab is an immunotherapy agent which trains your immune system to target your tumor in a more specific way than chemotherapy does.
This study has 3 phases- screening, treatment, and follow up. If you join the study, during screening we will test a sample of your tumor along with your blood. The tumor sample will be obtained at the same time as you are having surgery or a biopsy. Other testing will be done to make sure you are eligible to receive treatment. If you are eligible for treatment, you will receive five 21 day cycles of anti-cancer medication (induction chemotherapy) along with naxitamab. You will have to stay in the hospital to receive this treatment for at least 6 days of each 21 day cycle. If your screening testing also shows a certain genetic change in your tumor, we may also add a medication that is targeted at that change. If your tumor does not respond adequately to the initial cycles, we may give up to three additional 21 day cycles of chemotherapy with naxitamab. You will also have procedures at certain timepoints during induction that are standard of care for your tumor. These include collecting stem cells for use later in your therapy after Cycle 2. After Cycle 4, you will have surgery to remove as much of the tumor as possible. The treatment phase will last about 8 months, after which you will be in follow up. During your time on the study, we will ask to collect research samples of blood, bone marrow, and tumor. We will be monitoring your progress and health throughout your time on treatment and in follow up.
≤ 26 years of age at initial diagnosis and > 12 months of age at time of enrollment
Receiving any investigational drug
The opioid epidemic among Pennsylvania immigrants: Implications for treatment practices
We plan to interview PA immigrants who have first-hand experience with opioid abuse or who have friends/family/neighbors with opioid abuse experiences. The goal is to highlight areas for improvement, regarding access to treatment and quality of treatment for immigrants. We hypothesize that immigrant status uniquely impacts this group and their rehabilitation journeys, but this has not yet been studied.
There will be one semi-structured, qualitative interview over Zoom, for about 45 minutes. Interviews may be in-person if there is no Zoom access.
$75.00 gift card
PA resident
18 years of age and older
Experience with opioid abuse
Friend or family member with opioid abuse experience
U.S. citizen
Below 18 years of age
No opioid abuse experience
diagnosis of an intellectual/developmental disability
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects
Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS. This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.
You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash
Environmental Exposure and ALS
We are hoping to learn more about the relationship between environmental exposures and developing ALS (Amyotrophic lateral sclerosis - Lou Gehrig’s Disease). Our focus will be on heavy metal and other potential exposures that might occur throughout life at home, in the workplace, and during military service, as examples. Study participants will attend a single study visit to provide information about environmental exposure and to donate blood and toenail clippings.
- Attend a single study visit lasting 1-2 hours - Informed consent - Complete environmental exposure questionnaire - Blood sample collection - Collection of toenail clippings
$20
ALS diagnosis (for cases)
Cognitive ability to consent or legally authorized represenative
Understanding the factors affecting job satisfaction and unemployment in the USA.
This study will assess the various factors that influence job satisfaction, including salary, benefits, work-life balance, work environment, job security, and opportunities for advancement. It will also aim to measure the main causes for unemployment and the impact on general well being.
Complete an electronic survey which will take about 20 minutes on average
residing in USA
residing outside USA
Linking brain network dynamics to smoking-related behavior
Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.
There will be two in-person visits, both will involve completion of computerized questionnaires and one will involve completing and MRI scan
175
Age 21-65
Claustrophobic
School Choice: Factors in Making a Choice and the Impact of Economics
The purpose of this study is to communicate with decision makers (parents and guardians) to identify the processes and considerations used when seeking and determining information relative to school choice. This study will examine those factors and see if there is equality among socio economic groups.
guardian
child in elementary / middle school
live in or around a low income community
not a parent or guardian
BCC017: Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG)
This study is being done to learn if a vaccine made in the laboratory from your tumor and your immune cells is safe to give to you to treat your tumor. It is believed that the body’s immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use your tumor and immune cells from your blood to make a vaccine that we hope will stimulate your T-cells to kill tumor cells and leave your normal cells alone.
You will need routine (standard of care) testing for your tumor, as well as research tests and procedures including further analysis of your tumor sample, generation and review of a personalized genetic report, and procedures to collect certain cells for different infusions and creation of specialized cellular vaccines. You will then be offered and placed on a treatment plan. As a subject in this study you will remain in this study until you complete vaccine therapy as long as you have no disease progression or unless you need to come off study for another reason.
For Neuroblastoma must be >12 months and ≤ 30 years of age
For DIPG must be ≥ 3 years and ≤ 30 years of age
Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection
BCC021: Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
The purpose of this study is to evaluate the investigational drug Silmitasertib (CX-4945) (a pill taken by mouth) in combination with chemotherapy drugs standardly used for your tumor type. An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.
You will undergo a number of standard tests and research-related procedures before being able to enroll on this study.
Examining views associated with physical exercise and its connection to diet, social connectivity, and stress reduction: Online Focus Groups
The primary objective of this study is to examine, via online focus groups, the perceptions that are held by potentially-eligible subjects in the PSH DPP program in regard to the importance of physical exercise, particularly within the context of diet, social connectivity, and stress reduction. These perspectives will then be used to help develop, test, and refine additional motivational text messages that can be used in a text messaging intervention. Participants will receive a $25.00 gift card.
Body Mass Index ≥25 kg/m2 (≥23 kg/m2 if Asian)
Have no previous diagnosis of type 1 or type 2 diabetes
Fluent in English
Body Mass Index <25 kg/m2 (<23 kg/m2if Asian)
Previous diagnosis of type 1 or type 2 diabetes
Not fluent in English
Application of graph theory to both resting-state and task-based fMRI data to uncover brain-behavior relationships related to therapy outcomes in aphasia
This project will use fMRI to examine changes in the brain related to behavioral therapy outcomes in persons with aphasia. We aim to recruit twenty persons with aphasia. Each participant will receive 4 MRI scans. Between scan 1 and scan 2, no therapy will be provided (10 week break). Between scan 2 and scan 3, ten weeks of word finding therapy will be provided. Between scan 3 and scan 4, no therapy will be provided (10 week break). The therapy used is abstract word retrieval training. The results of this project will help inform rehabilitation practices in aphasia.
There will be 4 fMRI scans. After the first and third fMRI scans, there will be an assessment. After the second fMRI scan, there will be 10 weeks of treatment.
$460
Sustained stroke at least 6 months ago
Right-handed
Native English speaker
Completed at least a high school education
History of other acquired neurological disorder (e.g., TBI)
History of developmental disorder (e.g., autism)
History of psychological disorder (e.g., schizophrenia)
Unsafe to receive MRI (e.g., pacemaker)
Analyzing Student Newspaper Political Coverage
This study involves a content analysis of student newspaper political articles, as well as a survey of student journalists regarding their views about how politics are reported in student media.
Involvement on student newspaper
Involvement with other student media
Health Apps to Mitigate COVID-19 Risk Survey
With the COVID-19 pandemic affecting everyone’s daily routine, our lives have changed drastically. The health of ourselves, families, friends, and communities is our biggest concern and finding a cure to this problem is still underway The purpose of this survey is to analyze how people are taking control of their health using various health applications forms.
User Mobility and Graph Learning in Virtual Reality
This study investigates how the interaction affects how well 3D graphs are understood and remembered in virtual reality, and how individual differences in spatial ability affect and interact with memory and understanding.
Coping with it All from Labor to Maternity
The CALM Project is looking to learn how different birthing classes prepare child-bearers for parenthood. Participants attend a free birthing class between their 20th and 37th weeks of pregnancy with their partners and fill out three questionnaires during pregnancy and postpartum. Three months after their baby is born, they are video-recorded interacting with their baby in their home and have their brain scanned using MRI. We aim to understand how different childbirth classes support mothers' well-being and bonding with their babies.
Women are asked to 1. complete 3 self-report questionnaires online during pregnancy and after their baby is born (45 minutes each) 2. attend a childbirth preparation class (from a few hours to a 9-week class) 3. participate in 2 in-person sessions (1.5 hours each): a videorecording with their baby in the home and a brain scan using MRI at Penn State Hershey Medical Center.
$160 + free birthing class
At least 18 years old
Speaks English
Pregnancy complications that would prevent you from participating in an online class
Psychological and Biological Determinants of Eating Disorder Pathology in Endurance and Aesthetic Athletes
The purpose of this study is to investigate psychobiological factors that impact the development and manifestation of eating disorder (ED) pathology in elite male and female athletes before and during their competitive season.
The purpose of this voluntary research study is to assess how changes in stress, cognitive flexibility, response inhibition, and reward delay predict the trajectory of eating disorder behaviors and associated side effects of energy deficiency from the off-season compared to the competitive season. Your participation in this study will last approximately the duration of one season of your sport, specifically 4-weeks of data collection prior to season commencement (baseline), 4-weeks of data collection during peak competition season, and 4-weeks of data collection during off-season. The total time spent in the lab will be approximately 10-14 hours. Procedures will occur three times and measurements will be taken twice following baseline measures (once during the peak competition season, once during off-season), if you agree to do so.
$50
A member of a Penn State NCAA Division 1 Sports team, or Penn State affiliated competitive club team, or competitive community sport team
Exercising without any training modifications that reduce training participation.
non-smoker
No serious of chronic health conditions
Currently a smoker or history of regular smoking (including nicotine products, e-cigarettes, vaping)
Medications influencing metabolic or endocrine factors (e.g., hormonal use in previous 6 months)
Medical instability or history of psychosis
Vasectomy (male) or Hysterectomy or oophorectomy (female)
Public Perception of Public Health Wireless Emergency Alerts
The objectives of this study are to understand attitudes, emotional response, and behavioral intention related to receiving COVID-19 public health messaging via the Wireless Emergency Alert system.
Received a Wireless Emergency Alert in November
Did not receive a Wireless Emergency Alert in November
RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC (PSCI# 20-118) (NRG-LU007)
The purpose of this study is to compare the usual treatment of the immune therapy drug atezolizumab alone, to using radiation therapy plus the usual treatment. The addition of radiation to the usual treatment could shrink your cancer or prevent it from returning. This study will help the study doctors find out if this different approach is better, the same or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients or extends your time without disease compared to the usual approach.
The purpose of this study is to compare the usual treatment of the immune therapy drug atezolizumab alone, to using radiation therapy plus the usual treatment.
measurable disease (per RECIST) and 3 or fewer observable liver metastases and no evidence of progressive disease at enrollment
Patients presenting with a pleural effusion will be eligible if thoracentesis is cytologically negative and non-bloody
ECOG Performance Status of 0-2 at the time of registration
Age ≥ 18
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 5 years prior to randomization
Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid therapy of > 10 mg prednisone daily or equivalent at the time of registration
Patients who have had immunotherapy-induced pneumonitis
History of recent myocardial infarction within 6 months prior to registration
Phase II, questionnaire for “BRITE Synergy: Developing and Validating a Framework for Measuring Resilience in Low-Income Housing in the Post-Pandemic World”
This study includes the questionnaire related to "BRITE Synergy: Developing and Validating a Framework for Measuring Resilience in Low-Income Housing in the Post-Pandemic World" which has been previously submitted. The objective of this part of the research is examining the extent to which energy burden linked to the use of inefficient appliance within the context of a changing climate can be a good proxy for community resilience and if the ongoing building electrification drive.
Participants will be asked to complete an online survey via a link that will be accessed.
10 random participants will receive $20 gif cards.
Subjects must be living in the US
Living outside the US